Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...

Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

We led a study to find out how genes have such a significant influence on why humans (and dogs) become overweight. It was their reputation for greediness that led us to focus on Labrador retrievers.

Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...

In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in rare melanocortin-4 receptor (MC4R) pathway diseases and ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

It turned out increased obesity risk in Labradors was linked to the same genes and mechanisms that cause obesity in humans.